Funded Biotechnology Startups in Boston
Recent disclosed rounds in Boston biotechnology skew toward large financings: the largest disclosed amount is $150M for Scorpion Therapeutics (2024-07-16),…
Recent disclosed rounds in Boston biotechnology skew toward large financings: the largest disclosed amount is $150M for Scorpion Therapeutics (2024-07-16), which dwarfs the next-largest disclosed entries (e.g., Verve Therapeutics at $125M on 2023-11-28, Elektrofi at $112M on 2024-08-27, and Compass Therapeutics at $120M on 2025-08-12). At the low end, the smallest disclosed amount is $100K for Eascra Biotech (2025-05-16), while multiple rows are clustered in the late-2024 to early-2025 window (e.g., several financings from 2024-10 through 2025-04), indicating repeated near-term capital raises rather than a uniform spread.
Stage and disclosure are also uneven. Five of the 50 rows are marked “undisclosed” (Bambusa Therapeutics on 2025-11-20; Dewpoint Therapeutics on 2025-09-13; Superluminal Medicines on 2025-08-14; PathMaker Neurosystems on 2025-06-02; GPx on 2024-11-12), and 16 of the 50 rows use “Series Unknown” (including Allarity Therapeutics on 2026-03-06 and Seaport Therapeutics on 2026-03-03). The dataset runs from 2023-09-11 (APRINOIA Therapeutics) through 2026-03-06 (Allarity Therapeutics), with the most recent entry on 2026-03-06.
Most recent rounds
50 shownRelated listings
Frequently asked
Which disclosed round is the clear outlier, and how does it sit relative to the next-largest disclosed amounts?
Scorpion Therapeutics’ $150M round dated 2024-07-16 stands above the rest of the disclosed amounts; the next-largest disclosed figures include Compass Therapeutics at $120M (2025-08-12), Verve Therapeutics at $125M (2023-11-28), and Elektrofi at $112M (2024-08-27), all below $150M.
Is there a concentration of rounds in a particular time window rather than a steady cadence?
There is noticeable clustering from late 2024 into early 2025: for example, multiple rounds fall between 2024-10-02 (Asymmetrex at $2M) and 2025-04-09 (Solu Therapeutics at $41M), including Axonis Therapeutics at $115M (2024-10-30), Elektrofi at $112M (2024-08-27), and Entrada Therapeutics at $100M (2024-06-24).
What does the disclosure pattern look like: how often are amounts or stages missing?
Five of the 50 rows show an “undisclosed” amount (Bambusa Therapeutics 2025-11-20; Dewpoint Therapeutics 2025-09-13; Superluminal Medicines 2025-08-14; PathMaker Neurosystems 2025-06-02; GPx 2024-11-12). Separately, 16 of the 50 rows are labeled “Series Unknown,” including Allarity Therapeutics (2026-03-06, $20M) and Elucid (2025-10-22, $37M).
Which stage labels dominate the disclosed entries, and what share of rows are non-specified by stage?
“Series Unknown” appears 16 times across the 50 rows (e.g., Seaport Therapeutics on 2026-03-03 at $15M; Ensoma on 2025-09-26 at $53M). Many other rounds carry specific labels (e.g., Precede Biosciences at $64M on 2026-01-12 as Series B and Third Arc Bio at $52M on 2026-02-04 as Series A), but non-specified stage naming is frequent.
Are there extremes at the low end worth attention, alongside the large-ticket rounds?
Yes. The smallest disclosed amount is $100K for Eascra Biotech on 2025-05-16, which sits far below most other disclosed rounds (e.g., Manifold Bio at $1M on 2025-10-08 and Propedix at $800K on 2024-11-21 are still well above $100K). This makes Eascra’s round an outlier within the disclosed range.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.